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Abstract
Background: The development of obesity has been linked to an inflammatory process, and the role of adipose
tissue in the secretion of pro-inflammatory molecules such as IL-6 or TNFalpha has now been largely confirmed.
Although TNFalpha secretion by adipose cells is probably induced, most notably by TLR ligands, the activation and
secretion pathways of this cytokine are not yet entirely understood. Moreover, given that macrophagic infiltration is
a characteristic of obesity, it is difficult to clearly establish the level of involvement of the different cellular types
present within the adipose tissue during inflammation.
Methods: Primary cultures of human adipocytes and human peripheral blood mononuclear cells were used. Cells
were treated with a pathogen-associated molecular pattern: LPS, with and without several kinase inhibitors.
Western blot for p38 MAP Kinase was performed on cell lysates. TNFalpha mRNA was detected in cells by RT-PCR
and TNFalpha protein was detected in supernatants by ELISA assays.
Results: We show for the first time that the production of TNFalpha in mature human adipocytes is mainly
dependent upon two pathways: NFkappaB and p38 MAP Kinase. Moreover, we demonstrate that the PI3Kinase
pathway is clearly involved in the first step of the LPS-pathway. Lastly, we show that adipocytes are able to secrete
a large amount of TNFalpha compared to macrophages.
Conclusion: This study clearly demonstrates that the LPS induced activation pathway is an integral part of the
inflammatory process linked to obesity, and that adipocytes are responsible for most of the secreted TNFalpha in
inflamed adipose tissue, through TLR4 activation.
Background
It is now known that the development of obesity is linked
to an inflammatory process. It has also been demonstrated
that adipose tissue plays a role in the secretion of certain
pro-inflammatory molecules such as IL-6 or TNFalpha.
Numerous studies have shown that these cytokines, and in
particular TNFalpha, provoke an insulin desensitization
phenomenon, which could result in a metabolic syndrome
that could in turn evolve into type 2 diabetes [1-5]. How-
ever, the mechanisms of adipose tissue TNFalpha secretion
are not yet well understood. In effect, leukocyte infiltration,
particularly of macrophages, is observed in the
development of obesity [6,7]. As far as the secretion of
TNFalpha is concerned, it is difficult to determine the level
of involvement of the different cell types present in adipose
tissue; a problem that is still debated today. LPS is a well
preserved component of the external part of the Gram
negative bacterial cell wall. This molecule is recognized by
the innate immune system via the Toll Like Receptor 4
(TLR4) present, in particular, on monocytes/macrophages.
The activation of the receptor leads to the secretion of
numerous immunoregulatory molecules, including pro-
inflammatory factors, such as TNFalpha. Thus, TLR4 acti-
vation contributes to the obesity inflammatory process. In
earlier work, our team demonstrated that in a similar way
to cells of the innate immune system, mature human adipo-
cytes express the LPS receptor TLR4, with activation lead-
ing to the secretion of TNFalpha [8]. However, certain
recent studies have questioned these results, especially the
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TNFalpha.
In the first part of this study, we identified the TLR4
signalling pathways activated by LPS (NFkappaB and
p38 MAP Kinase), which lead to the secretion of TNFal-
p h ab ym a t u r eh u m a na d i p o c y t e s .W eh a v ea l s os h o w n
that PI3Kinase is implicated in this process. In addition,
our work clearly shows that adipocytes are an integral
part of the obesity linked inflammatory process, and
that the LPS induced activation pathway is specific to
this cell. Moreover, we have also characterized the level
of TNFalpha secretion in adipocytes by comparison with
macrophages in primary culture.
Methods
Origin of adipose tissue samples
Subcutaneous (abdominal, buttocks, hips and thighs) tis-
sue samples of human white fat were obtained from
normal weight or slightly overweight human subjects
(exclusively females, mean body mass index 25.13 ± 3.45
kg/m
2) undergoing liposuction, performed under general
anesthesia, for cosmetic reasons (aged between 27 and
58 years, mean 40.26 years). Apart from oral contracep-
tion, the subjects were not receiving treatment with pre-
scribed medication at the time of liposuction. A total of
1 3s a m p l e sw e r eo b t a i n e df r o m1 3p a t i e n t s .T h es t u d y
was approved by the Ile de la Réunion ethics committee
for the protection of persons undergoing biomedical
research.
Primary culture of human adipocytes
Cultures were prepared as described previously [8,9].
Briefly, tissue samples obtained by liposuction were
digested for 30 min at 37°C in Ringer-Lactate buffer
containing 1.5 mg/mL collagenase (NB4, SERVA, Ger-
many, PZ activity 0.175 U/mg). The floating adipocytes
(mature adipocytes) were rinsed twice in Ringer-Lac-
tate. Cells were plated (30 000 cells) in 24-well tissue
culture plates with 199 culture medium supplemented
with: 1% FBS (PAN Biotech, France), amphotericin B,
(5 μg/mL), streptomycin (0.2 mg/mL) & penicillin (200
U/mL) (PAN Biotech, France), 66 nM insulin (Umuline
R a p i d e ,L i l l y ,F r a n c e ) ,2g / Lg l u c o s e ,8μg/L biotin and
4 μg/mL pantothenate. Cells were then maintained at
37°C in 5% CO2 for a period of 24 hours prior to the
experiments.
Human peripheral blood mononuclear cell culture
Mononuclear cells were separated from blood using the
Histopaque® method. 30 mL of Histopaque® was over-
layed with 15 mL of blood, and centrifuged without the
brake for 20 min at 800 g, which allows mononuclear
cells to form a distinct layer at the plasma-Histopaque®
interface. Cells were washed twice and plated at 37°C in
5% CO2 in a 96 well-plate in RPMI with 10% FBS, peni-
cillin (100 U/mL), streptomycin (100 μg/mL) and
amphotericin B (25 ng/mL). After 2 hours, cells were
washed, and the number of cells was estimated at 8 ×
10
4 cells/well. Cell number and viability were established
by Trypan blue exclusion (Trypan solution 0.4%, Sigma-
Aldrich, France). Medium was then changed after 18
hours and cells were treated with LPS.
Human TNFalpha ELISA
Following LPS stimulation for 6 hours, with or without
inhibitors, samples of medium were assayed for TNFal-
pha content with Ready-SET-Go human ELISA kits
(Cliniscience, Montrouge, France) according to the man-
ufacturer’s instructions.
RNA extraction, reverse transcription and real-time
quantitative PCR
C e l l sf r o m6w e l l s( 3×1 0
5 cells) were extracted with
500 μLo fT R I z o l ™ reagent (Invitrogen, France). Total
RNA was isolated and precipitated according to the
manufacturer’s instructions. 1 μg of total RNA was
reverse-transcribed using random heptamer primers
(Eurogentec, Belgium) with MMLV (Invitrogen, France).
1 μl of reverse-transcribed RNA was amplified by PCR
on an ABI PRISM 7000 thermal cycler (Applied Biosys-
tems, France) using the Taqman™ Master Mix Kit (Euro-
gentec, Belgium). The 18S ribosomal RNA (rRNA) gene
was used as a reference. Quantification of target mRNA
was carried out by comparison of the number of cycles
required in order to reach the reference and target
threshold values (ΔΔCT method) (see Table 1 for Pri-
mers and Probes Sequences).
Protein extraction
Cells were rinsed twice after removing medium. Proteins
were extracted with 1000 μL of lysis buffer (50 mM
Tris-HCl pH 7.4, 150 mM NaCl, 1% triton, 1 mM
EDTA, 1/20 (v/v) anti-protease cocktail (Sigma-Aldrich,
France) per 6 wells. The volume of lysate obtained was
mixed with 4 volumes of methanol, 1 volume of chloro-
form and 2 volumes of water. After vortexing, the
Table 1 Primers and probes sequences
Gene Primers Probes
TNFalpha 5’-AACATCCAACCTTCCCAAACG-3’
3’-GACCCTAAGCCCCCAATTCTC-5’
5’-FAM-CCCCCTCCTTCAGACACCCTCAACC-TAMRA-3’
18S 5’-CGCCGCTAGAGGTGAAATTCT-3’
3’-CATTCTTGGCAAATGCTTTC-5’
5’-FAM-ACCGGCGCAAGACGGACCAGA-TAMRA-3’
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Page 2 of 12samples were centrifuged for 5 min at 20 000 g. The
upper phase was taken and mixed with 3 volumes of
methanol and centrifuged as before. The pellet was
resuspended in Tris 50 mM, Na Cl 145 mM, SDS 0.5%
pH 7.5.
Western blot analysis
SDS-PAGE was performed according to the LaemmLi
protocol (1970), under reductive conditions with 12.5%
running gels and 4% stacking gels. Gels were run for 2
hours at 4°C and 15 V, and then blotted onto a nitrocel-
lulose membrane (Millipore, France) using a liquid
transfer system (Biorad). Membranes were soaked for 30
min in TBS buffer (138 mM NaCl, 15 mM Tris-base)
containing 0.05% (v/v) Tween 20, 0.05% Triton, 5% BSA.
Total human p38 MAP Kinase protein was detected
with anti p38 MAP Kinase antibody (Cell Signaling,
Ozyme, Saint Quentin Yvelines, France) at a 1/2000
dilution. Human phosphorylated p38 MAP Kinase pro-
tein was detected with anti-phospho-p38 MAP Kinase
antibody (Thr180/Tyr182) (Cell Signaling, Ozyme, Saint
Quentin Yvelines, France) antibody at a 1/1000 dilution.
The membranes were incubated in TBS buffer (138 mM
NaCl, 15 mM Tris-base) containing 0.05% (v/v) Tween
20, 0.05% Triton, 5% BSA with the primary antibody for
2 hours at room temperature. Membranes were washed
3 times for 10 min in TBS buffer (138 mM NaCl, 15
mM Tris-base) containing 0.05% (v/v) Tween 20, 0.05%
Triton. This was followed by incubation with alkaline
phosphatase-conjugated polyclonal anti-rabbit immuno-
globulin (1/1000) in TBS buffer (138 mM NaCl, 15 mM
Tris-base) containing 0.05% (v/v) Tween 20, 0.05% Tri-
ton, for one hour at room temperature. After four 5
min washes with TBS buffer, development was com-
pleted with an enzymatic assay (ECL, Amersham Bios-
ciences) and visualized with a Kodak 2000R Image
station.
Statistical analysis
Statistical analysis was performed using Microsoft Excel
software. Differences were tested for significance (P <
0.001, P < 0.01 and P < 0.05) by the unpaired Student’s
t-test.
Results
LPS induced TNFalpha synthesis is linked to the
activation of the NFkappaB and the p38 MAP Kinase
pathway
The role of the NFkappaB pathway in the gene expres-
sion and secretion of TNFalpha has been determined
through the use of a specific inhibitor to this pathway
(6-Amino-4-(4-phenoxyphenylethylamino) quinazoline,
Calbiochem: NFkappaBi). Figure 1A shows that the use
of NFkappaBi (0.1 μM, 0.5 μM and 1 μM) causes a dose
dependent reduction in the LPS induced activation of
TNFalpha secretion. The maximum inhibition of
activation (around 40%) is obtained with a concentration
of 1 μM. In a similar way NFkappaBi is responsible for a
30% and 70% reduction in TNFalpha gene transcription
at 5 and 6 hours, respectively, following treatment with
LPS (Figure 1B).
T h er o l eo ft h ep 3 8M A PK i n a s ep a t h w a yi ng e n e
expression and secretion of TNFalpha has been deter-
mined via the use of a pathway inhibitor (SB202190,
Sigma-Aldrich). SB202190 provokes around a 60%
decrease in the LPS induced activation of TNFalpha
secretion (Figure 1A). In a similar way SB202190 treat-
m e n tr e s u l t si na2 - f o l dr e d u c t i o ni nL P Si n d u c e d
TNFalpha gene transcription (Figure 1B).
Figure 2 confirms that the action of LPS on mature
adipocytes results in p38 protein phosphorylation with a
peak obtained 5 minutes after stimulation. The quantity
of phosphorylated p38 protein subsequently decreases
and is no longer detectible 20 minutes after treatment
with LPS. The use of SB202190 (1 μM) greatly decreases
the LPS induced phosphorylation of the p38 protein,
resulting in a level that is near identical to the control.
Studies have demonstrated that the p38 pathway can
activate the NFkappaB signalling pathway [10]. We
therefore investigated whether the p38 MAP Kinase and
NFkappaB pathways were independent or not. The pre-
sence of the two inhibitors (SB 202190 and NFkappaBi)
leads to around an 85% inhibition in the production of
TNFalpha (Figure 1A). Thus it would seem that the two
activation pathways are probably independent.
A great deal of work on primary human macrophage
cultures as well as on immortalized cell lines shows that
LPS systematically activates the Erk1/2 MAP Kinase
pathway [11-14]. We therefore investigated whether this
pathway is implicated or not in mature human
adipocytes.
p42/44 MAP Kinase and JNK pathways do not influence
LPS induced TNFalpha synthesis
We have used two specific inhibitors of the MAP Kinase
Kinase pathway; GW5074 (5 μM, Sigma-Aldrich) that
selectively inhibits the Raf/MEK/ERK2 Kinase cascade
by blocking the activity of Raf-1; and U0126 (1 μM,
Sigma-Aldrich) that specifically inhibits MEK1 and
MEK2. In both cases, the level of LPS induced TNFal-
pha secretion was not modified and corresponded to the
level of secretion of the control cells (Figure 3A). Simi-
larly, the use of an inhibitor to the c-jun NH2 terminal
Kinase (1 μM, JNK inhibitor I, Calbiochem) does not
modify the synthesis of TNFalpha during treatment with
LPS.
PKA pathway does not influence LPS induced TNFalpha
synthesis
In an identical way, Protein Kinase A (PKA) has been
implicated in the inhibition of the LPS activation path-
ways [15]. We therefore analyzed whether this pathway
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secretion by using an inhibitor of PKA (Myristoylated
Protein Kinase A Inhibitor Amide 14-22, Calbiochem).
This inhibitor does not alter the levels of TNFalpha
secretion (Figure 3B).
PI3Kinase pathway is implicated in LPS induced TNFalpha
synthesis
The role of PI3Kinase in the secretion and genetic
expression of TNFalpha was determined by the use of
two different inhibitors to this pathway (wortmannin,
Sigma-Aldrich and LY294002, Cayman Chemical,
France). Figure 4A1 shows that the use of wortmannin
(1 and 5 μM) strongly increases the activation of LPS
induced TNFalpha secretion (more than 2-fold). In a
similar way, wortmannin increases LPS induced TNFal-
pha gene transcription by a factor of 2 (Figure 4B). The
use of a protein kinase C inhibitor (Chelerythrine chlor-
ide, Sigma-Aldrich, 1 μM) restores TNFalpha secretion
to a level comparable to treatment with LPS alone (Fig-
ure 4A1). Surprisingly, the use of LY294002 (100 and
5 0 0n M )d o e sn o tg i v et h es a m er e s u l ta st h a to b t a i n e d
with wortmannin. Treatment with LY294002 leads to a
15% down-regulation of LPS-induced TNFalpha secre-
tion (Figure 4A2).
Specificity of the action of LPS on mature human
adipocytes
The activation of TNFalpha secretion by LPS is receptor
specific and dependent upon the bacterial endotoxin
Figure 1 Activation of p38 MAP Kinase and NFkappaB pathways regulate LPS induced TNFalpha synthesis from human mature
adipocytes. Panel A: Effect of NFkappaB and p38 inhibitors on TNFalpha secretion. The concentrations of TNFalpha (pg/mL) were
determined at 6 hours in the medium of mature adipocyte cultures treated or not with: 1 μg/mL of LPS alone; LPS and increasing
concentrations of NFkappaB inhibitor (NFkBi 0.1, 0.5 and 1 μM); LPS and increasing concentrations of p38 MAP kinase inhibitor (SB, 0.1, 0.5, 1 and
5 μM); LPS and NFkBi (1 μM) + SB (1 μM). The graph represents the mean ± SE of the results from one patient (n = 6 for each condition),
representative of three experiments on three different patients. ***P < 0.001%, *P < 0.05%, versus cells treated with LPS alone. Panel B:
TNFalpha gene expression. TNFalpha gene expression was determined at 4, 5 and 6 hours of treatment in mature adipocyte cultures, treated
or not with: 1 μg/mL of LPS alone; LPS and NFkappaB inhibitor (NFkBi, 1 μM); LPS and p38 MAP kinase inhibitor (SB, 1 μM); LPS and NFkBi (1
μM) + SB (1 μM). The graph represents the mean ± SD of the results from one patient (n = 5 for each condition), representative of two
experiments on two different patients. ***P < 0.001%, *P < 0.05%, versus cells treated with LPS alone.
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an anti-TLR4 antibody decreases by more than 5-fold the
activator effect of LPS (Figure 5B). Nevertheless, LPS
requires one or several partner components to be present
in the FBS in order to activate TLR4. The absence of FBS
in the culture medium strongly limits the LPS activation
of TNFalpha secretion (Figure 5A). Moreover, it is highly
probable that another TLR4-partner, CD14 [16], is pre-
sent in the serum, as CD14 is not present on the surface
of mature human adipocytes [17]. The use of anti-CD14
antibody confirms that the presence of CD14 is essential
to TLR4 signalling. This is demonstrated by the 6-fold
reduction in the LPS-effect brought about as a result of
antibody blocking (Figure 5C).
The goal of this work was not to identify all of the
partner components implicated in this process. How-
ever, we presume that LPS-binding protein (LBP) is
involved and probably present in the serum used in the
culture medium.
Macrophages are more sensitive to LPS, but adipocytes
secrete more TNFalpha
We evaluated the difference in the levels of TNFalpha
synthesis between human macrophages and mature
human adipocytes (both primary cultures). Figure 6
shows that macrophages were more sensitive to LPS sti-
mulation than adipocytes, as these cells were able to
respond to 5 ng/mL of LPS. Nevertheless, adipocytes
secreted more TNFalpha than macrophages when they
were treated with 1 μg/mL of LPS (around 4-fold more,
following normalization of the cell number).
Discussion
In a previous study, our team reported for the first time
that human adipose cells express constitutively two
receptors of innate immunity, TLR2 and TLR4 [8]. We
demonstrated that TLR2 and TLR4 were expressed at
relatively high concentrations (compared to a monocyte
cell line) on the surface of human mature adipose cells.
Stimulation with LPS, or with lipoteichoic acid (LTA),
two specific ligands of TLR4 and TLR2, respectively,
induced a strong increase in TNFalpha production. The
general mechanisms leading to the secretion of TNFal-
pha in mature human adipose cells have been demon-
strated in a previous study [18] and recently confirmed
by others [19]. Activation of NFkappaB [20-22], which
enables the activation of TNFalpha transcription, fol-
lowed by cleavage of the protein via a membrane metal-
loprotease, ADAM17 or TACE, leads to the release of
the soluble form of TNFalpha [23-25]. In the work that
is presented here, we show in detail the principal activa-
tion regulation pathways of the LPS induced secretion
of TNFalpha.
Thus, we show for the first time that the production
of TNFalpha in mature human adipocytes is mainly
dependent upon two pathways: NFkappaB and p38
MAP Kinase. Each of these pathways represents around
half of the signal that induces TNFalpha secretion. How-
ever, the combined use of high concentrations of inhibi-
tors to these two pathways shows that 10% to 15% of
the LPS activator effect in the synthesis and secretion of
TNFalpha RNA, can not simply be explained by the sti-
mulation of NFkappaB and p38 MAP Kinase. Thus, it is
certain that other minor transduction pathways exist.
We also show in mature human adipocytes that unlike
human monocytes/macrophages (in primary culture or
immortalized cell lines), the p42/44 MAP Kinase, JNK
or PKA pathways are not implicated in the secretion of
LPS induced TNFalpha [11-14,26,27]. This is
Figure 2 p38 MAP Kinase phosphorylation by LPS.M a t u r e
adipocyte cells were treated with LPS at 1 μg/mL for 5, 10 and 20
min, or with LPS + p38 MAP Kinase inhibitor (SB, 1 μM) for 5 min.
Proteins (50 μg per lane) were separated by SDS-PAGE and analyzed
by Western blotting using an anti-phospho-p38 MAP Kinase protein
antibody (Thr180/Tyr182, panel B). Loading equality was controlled
using antibody against the unphosphorylated isoform of p38 (panel
A). The data represent a typical result from two independent
experiments.
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is the adipose cells in culture that are responsible for
the secretion of TNFalpha, and not cells that may have
remained attached to the adipocytes (macrophages or
others), as has recently been suggested [28]. A number
of other details already published by our team show that
the existence of specific adipocyte secretion can no
longer be put in doubt as macrophages were not
detected in our adipocyte cultures [8,9,17].
Furthermore, our results demonstrate that PI3K is par-
tially implicated in LPS-activated adipocytes. However,
there is a conflict in our results, as the use of 2 different
PI3K inhibitors leads to opposite effects. Wortmannin
brings about the activation of TNFalpha secretion.
Indeed, this molecule is probably not specific to PI3K at
Figure 3 LPS induced TNFalpha protein secretion is independent of MAP Kinase Kinase, c-jun MAP kinase and protein kinase A
pathways. Panel A: Effect of Raf-1, MEK1/2 and c-jun kinase inhibitors. Concentrations of TNFalpha (pg/mL) were determined at 6 hours in
the medium of mature adipocyte cultures treated or not with: 1 μg/mL of LPS alone; LPS and Raf-1 specific inhibitor (GW5074, 5 μM); LPS and
MEK1/2 inhibitor (U0126, 1 μM); LPS and c-jun kinase inhibitor (JNKi, 1 μM). The graph represents the mean ± SE of the results from two patients
(n = 6 for each condition), representative of four experiments on four different patients. Panel B: Effect of protein kinase A inhibitor.
Concentrations of TNFalpha (pg/mL) were determined at 6 hours in the medium of mature adipocyte cultures treated or not with 1 μg/mL of
LPS alone or LPS and increasing concentrations of PKA specific inhibitor (PKAi, 20, 40 and 80 nM). The graph represents the mean ± SE of the
results from two patients (n = 6 for each condition).
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Page 6 of 12Figure 4 PI3Kinase plays a role in LPS induced TNFalpha secretion. Panel A1: Effect of PI3K inhibitor wortmannin and PKC inhibitor on
TNFalpha protein secretion. Concentrations of TNFalpha (pg/mL) were determined at 6 hours in the medium of mature adipocyte cultures
treated or not with: 1 μg/mL of LPS alone; LPS and PI3K inhibitor (wortmannin, 1 and 5 μM); LPS and PKC inhibitor (chelerythrine, 1 μM); LPS
and wortmannin + chelerythirine. The graph represents the mean ± SE of the results from one patient (n = 6 for each condition), representative
of four experiments on four different patients. ***P < 0.001%, vs. control cells; §§§SP < 0.001%, vs. LPS + wort1 treated cells; ###P < 0.001%, vs.
LPS + wort5 treated cells. Panel A2: Effect of PI3K specific inhibitor LY294002 on TNFalpha protein secretion. Mature adipocytes were
treated with LPS (1 μg/mL) and/or not with PI3K specific inhibitor, LY294002 (100 nM and 500 nM). The concentration of TNFalpha (pg/mL) was
determined in medium after 6 hours treatment. The graph represents the mean of the results from one patient (n = 6 for each condition),
representative of three experiments on three different patients. **P < 0.005%, *P < 0.01%, vs. LPS treated cells. Panel B: Effect of PI3K
inhibitors wortmannin on TNFalpha gene expression. TNFalpha gene expression in mature adipocyte cultures, treated or not with: 1 μg/mL
of LPS alone, or LPS and PI3K inhibitor (wortmannin, 1 μM) were determined at 3, 4, 5 and 6 hours of treatment. The graph represents the mean
± SD of the results from 2 patients (n = 5 for each condition, for each patient). ***P < 0.001%, *P < 0.05% vs. control cells.
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bit other kinases, such as PI4K [29,30], which is probably
implicated in limiting the LPS effect. Moreover, treat-
ment with LY294002 at 100 and 500 nM leads to a
decrease in TNFalpha secretion (Figure 4A2). As
LY294002 is strictly specific to PI3K [31], it is highly
plausible that PI3K is activated in the LPS-activated path-
way. This functional outline appears to be different to the
one identified in the monocyte/macrophage THP-1 cell
line [27]. In THP1 cells, PI3K phosphorylates Akt, which
in its active form is an inhibitor of the NFkappaB and
p38 MAP Kinase pathways. Moreover, Akt2 is able to
inactivate GSK3b, limiting the activation of NFkappaB. In
mature human adipocytes, it seems that PI3K has no
inhibitor effect upon NFkappaB and p38 MAP Kinase
pathways. Thus, PI3K could be considered as being a
third, minor, transduction pathway, as it accounts for
15% of the secretion. However, it would seem more rea-
listic to consider PI3K as an upstream molecule of p38
MAPK and NFkappaB pathways (Figure 7).
In addition, our work shows that the inhibitory action
of one or several unknown kinases (maybe PI4K) on the
Figure 5 LPS induced TNFalpha protein secretion requires co-factors and is dependant upon the CD14/TLR4 pathway. Panel A: FBS
effect on LPS induced TNFalpha secretion. The concentrations of TNFalpha (pg/mL) in the medium of mature adipocyte cultures treated or
not with increasing concentrations of FBS and 1 μg/mL of LPS, were determined at 6 hours. The graph represents the mean ± SE of the results
from two patients. ***P < 0.001%, *P < 0.05%, versus control cells. Panel B: Effect of TLR4 blocking antibody on TNFalpha secretion. The
concentrations of TNFalpha (pg/mL) in the medium of mature adipocyte cultures treated with 1 μg/mL of LPS, with or without 1 h of pre-
incubation with a blocking anti-TLR4 antibody (20 μg/mL, Clinisciences, Montrouge, France, clone HTA125) were determined at 6 hours. The
graph represents the mean ± SE of the results from two patients. ***P < 0.001%, versus cells treated with LPS alone. Panel C: Effect of CD14
blocking antibody on TNFa secretion. The concentrations of TNFa (pg/mL) in the medium of mature adipocyte cultures treated with 1 μg/
mL of LPS, with or without 1 h of pre-incubation with a blocking anti-CD14 antibody (5 μg/mL, Hycult biotechnology, clone 18D11) were
determined at 6 hours. The graph represents the mean ± SE of the results from one patient (n = 6 for each condition), representative of two
experiments on two different patients. ***P < 0.001%, versus cells treated with LPS alone.
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adipocytes. Human mature adipocytes and peripheral blood mononuclear cells were treated with a LPS dose-response (5, 10 ng/mL and 1 μg/
mL). TNFa concentrations in medium (pg/mL) were determined at 6 hours. Plating was 8 × 10
4 for macrophages and 3 × 10
4 for adipocytes.
The graph represents the mean ± SE of the results from one patient (n = 6 for each condition) for each cell type, representative of two
experiments on two different patients (macrophages) and representative of three experiments on three different patients (adipocytes).
Figure 7 Signaling pathways involved in LPS induced TNFalpha production in human adipocytes. LPS, with LBP and CD14 (coming from
medium) bind to TLR4 on mature human adipose cells. Binding activates two main pathways in the cells. One pathway leads to the activation
of NFkappaB (through TRAF6 and IKK). The other pathway passes through phosphorylated p38 MAP Kinase. Both pathways enable the activation
of TNFalpha transcription, followed by cleavage of the protein via a membrane metalloprotease, ADAM17 or TACE, leading to the release of the
soluble form of TNFalpha. The PI3K represents a third pathway, which activates NFkappaB and p38 MAPK. Another kinase, maybe the PI4K, plays
an inhibitory role in the LPS activation of these 2 pathways. As far as the PKC is concerned, it probably activates IKK, or the p38 MAPKs, or both
pathways. However, activation is only visible once the PI4K is inactive. It is therefore possible that PI4K constitutively inhibits PKC.
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PKC (Figure 7) since an inhibitor of this kinase, cheler-
ythrine, strongly limits the increase in the wortmannin
induced secretion of TNFalpha. Chelerythrine alone
does not modify the effect of LPS on TNFalpha, which
in a way would seem logical, since PKC activates
MEK1/2 classically; whilst LPS does not activate MEK1/
2 in mature adipocytes. On the other hand this observa-
tion is surprising because chelerythrine can also activate
the NFkappaB pathway in a classical way; although
apparently not in this cell type. To our knowledge, this
is the first time that PKC has been implicated, in this
way, in the secretion of TNFalpha.
Adipocytes have been shown to secrete large quanti-
ties of IL-6 as well as non-negligible amounts of TNFal-
pha [8,9] and there is increasing evidence that leads us
to suppose that adipocytes are highly implicated in the
inflammatory phenomenon associated with the develop-
ment of obesity. However, since the two cellular types,
adipocytes and macrophages, are capable of secreting
TNFalpha, it would be interesting to determine the pro-
portion of TNFalpha that returns to the leukocytic cells,
as well as to adipose cells. In our study, we have shown
that macrophages are more sensitive to LPS than adipo-
cytes, with macrophages being able to respond to 5 ng/
mL of LPS. Nevertheless, at 6 hours, macrophages
seemed to exhibit the same level of secretion when trea-
ted with LPS concentrations from 5 ng/mL to 1 μg/mL,
whereas the response of adipocytes was higher than
macrophages (around 4-fold), with a maximum level
obtained with 50 ng/mL (data not shown). The number
of TLR4 receptors on the surface of the cells could in
part explain these differences. Thus, when one considers
the differences in TNFalpha expression and the number
of mature adipocytes compared with the infiltrated leu-
kocyte cells in adipose tissue, the contribution made by
adipose cells can not be considered negligible. On the
contrary, their contribution could even turn out to be
highly significant. In adipose tissue, it is highly possible
that adipose inflammation occurs, leading to macro-
phage activation and infiltration. Taking into account
our data from research in this field, we believe that adi-
pocytes are responsible for most of the secreted TNFal-
pha in inflamed adipose tissue.
Moreover, we have noticed that between different adi-
pocyte cultures (coming from different patients), the
TNFalpha level in LPS treated-cells is highly variable
(from 60 pg/mL to 300 pg/mL). This could be
explained, at least in part, by the insulin sensitivity of
adipocytes. Indeed, patients could have different insulin
levels, resulting in differences in adipocyte insulin sensi-
tivity. It has been demonstrated by another group that
insulin has an anti-inflammatory effect [32]. Thus, the
insulin contained in the medium could act as an anti-
inflammatory molecule in some patients.
The underlying fundamental question that should be
asked is what are the factors that trigger inflammation
in adipose tissue? Recently, a new concept has emerged,
which attributes an important role to the bacterial envir-
onment of the digestive tract as well as to that of satu-
rated lipids in food. It has thus been demonstrated that
a high-fat diet increases the proportion of an LPS-con-
taining micro biota in the gut [33,34], and that mice
that do not express TLR4 or CD14 receptors are pro-
tected from this induced metabolic syndrome compared
to normal mice. Furthermore, it has been discovered
that in humans with type 2 diabetes, LPS plasma levels
are higher than in healthy subjects [4]. Finally, recent
work has shown clearly that TLR4 could also be acti-
vated, not only by LPS, but also by lipids in food, espe-
cially saturated ones, thus explaining the development
of insulin resistance [35-37]. However, the identity of
the principal cellular relays has yet to be identified. Our
studies suggest that mature adipocytes must be consid-
ered as serious candidates. It should be noted that
nearly all of the results presented in this article were
obtained with an LPS concentration of 1 μg/mL. This
concentration is relatively high and cannot reflect the
physiological data that has already been presented. How-
ever, the adipocyte TNFalpha results that we have
obtained demonstrate that this cell is sensitive to LPS,
since 100-fold less (10 ng/mL) concentrations of LPS
are capable of stimulating the production of TNFalpha.
In fact, mature adipocytes whether from subcutaneous
adipose tissue or visceral adipose tissue [38], certainly
play a crucial role in the in vivo secretion of TNFalpha
observed in obesity. This secretion of TNFalpha probably
participates in the development of obesity. This could
occur, in part, by the recruitment of adipose precursors,
as it has been recently reported in the literature[39].
Conclusion
This study demonstrates that the production of TNFal-
pha in mature human adipocytes is mainly dependent
upon two pathways: NFkappaB and p38 MAP Kinase,
and that PI3Kinase is involved in the first step of the
LPS-pathway. We have also provided evidence that adi-
pocytes are able to secrete a large amount of TNFalpha
compared to macrophages.
These data clearly attest that the LPS induced activa-
tion pathway is an integral part of the inflammatory
process linked to obesity, and that adipocytes are
responsible for most of the secreted TNFalpha in
inflamed adipose tissue, through TLR4 activation.
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